Skip to content

S. 2305 · 118th Congress (2023–2025)

Biosimilar Red Tape Elimination Act

This bill removes certain requirements for biosimilars to be designated as interchangeable. (Biosimilars that are designated as interchangeable may be substituted for the reference product at a pharmacy without a new prescription, depending on state pharmacy laws.)

Specifically, the bill establishes a presumption that an approved biosimilar is interchangeable with the reference product without the need for additional evidence from the manufacturer, and it removes the applicable exclusivity periods for a first interchangeable biosimilar (i.e., a product that is the first interchangeable biosimilar to be approved with respect to the reference product).

The Food and Drug Administration (FDA) may require a manufacturer of a biosimilar to conduct a safety study with respect to switching or alternating between the biosimilar and the reference product, but only after the FDA briefs certain members of specified congressional committees to explain why the study is necessary.

Show official title

A bill to improve the requirements for making a determination of interchangeability of a biological product and its reference product.

Expired in Senate committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to committee

This bill’s path

This is S. 2305’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Sen. Mike Lee (R-UT)
Cosponsors
4 cosponsors

3 original · 1 later

  1. Sen. Mike Braun (R-IN)· Original · Jul 13, 2023
  2. Sen. Ben Ray Luján (D-NM)· Original · Jul 13, 2023
  3. Sen. J. D. Vance (R-OH)· Original · Jul 13, 2023
  4. Sen. Rand Paul (R-KY)· Later · Sep 11, 2023
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources
  3. Expired

    Introduced → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Jul 13, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (2)
  1. Biosimilar Red Tape Elimination Act

    Display title, Short title · Introduced in Senate

  2. A bill to improve the requirements for making a determination of interchangeability of a biological product and its reference product.

    Official title · Introduced in Senate